Mumbai, April 5 -- The newly approved indication allows Osimertinib to be used in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

The company said that this approval paves the way for the marketing of Osimertinib Tablets 40 mg and 80 mg (TAGRISSO) in India for the specified additional indication, subject to the receipt of any related statutory approvals.

AstraZeneca Pharma India is engaged in the business of manufacture, distribution, and marketing of pharmaceutical products and also provides clinical trial services to an overseas group compa...